General Announcement::ASX:TLX; Nasdaq:TLX: FDA Approves New Prostate Cancer Imaging Agent Gozellix

Issuer & Securities

Issuer/ Manager
TELIX PHARMACEUTICALS LIMITED
Securities
TELIXPHAR A$650M2.375%N290730 - XS2862961492 - JWQB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
21-Mar-2025 05:56:56
Status
New
Announcement Sub Title
ASX:TLX; Nasdaq:TLX: FDA Approves New Prostate Cancer Imaging Agent Gozellix
Announcement Reference
SG250321OTHR00ME
Submitted By (Co./ Ind. Name)
Genevieve Ryan
Designation
Company Secretary
Effective Date and Time of the event
21/03/2025 17:00:00
Description (Please provide a detailed description of the event in the box below)
ASX:TLX; Nasdaq:TLX: FDA Approves New Prostate Cancer Imaging Agent Gozellix

Attachments

20250321 Gozellix Approval Announcement vFINAL.pdf
Total size =144K